Article
Triplet therapy with gilteritinib, venetoclax, and azacitidine for relapsed/refractory FLT3mut acute myeloid leukemia.
Leukemia research - 1 Oct 2024
Fu Qiang, Wang Yunqi, Liu Hongtao, Gao Haitao, Sun Wei, Jiang Qian, Jiang Hao, Liu Kaiyan, Huang Xiaojun, Tang Feifei
Abstract excerpt
The FMS-related tyrosine kinase 3 (FLT3) inhibitor gilteritinib is standard therapy for relapsed/refractory (R/R) FLT3-mutated (FLT3mut) acute myeloid leukemia (AML) but the overall survival (OS) is only approximately 20 % and few patients achieve deep and/ or durable response. We retrospectively analyzed 29 R/R FLT3mut AML patients treated on triplet regimens (gilteritinib+ venetoclax［VEN] +azacitidine［AZA])....
Topics
- Humans
- fms-Like Tyrosine Kinase 3
- Male
- Leukemia, Myeloid, Acute
- Female
- Middle Aged
- Sulfonamides
- Aged
- Antineoplastic Combined Chemotherapy Protocols
- Bridged Bicyclo Compounds, Heterocyclic
- Retrospective Studies
- Aniline Compounds
- Adult